Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

    ... Allogeneic bone marrow transplantation from either HLA -matched sibling or matched unrelated donor cures about 70 ... rapidity of availability, requirement of less than perfect HLA match, and lower rates of graft versus host disease compared to mismatched ...

    Clinical Trial last updated 04/25/2016 - 2:18pm.

  2. Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

    ... which are matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. Each cord must ...

    Clinical Trial last updated 06/06/2016 - 12:58pm.

  3. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy

    ... on the outcome of 367 MDS patients transplanted from HLA -identical siblings or HLA allele-matched unrelated donors. RESULTS: According to the ...

    Research Article last updated 04/08/2015 - 9:59am.

  4. Adoptive Transfer of Haplo-identical DLI for AML and MDS

    ... followed by donor lymphocyte infusion (DLI) from HLA -haploidentical donors is a safe procedure that will not cause Graft ... (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation. Biological: DLI HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours ...

    Clinical Trial last updated 05/03/2016 - 9:59am.

  5. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... 0.5-75 years Suitable first-degree related, HLA haploidentical or HLA-matched donor Eligible diagnoses: a. Low-grade non-Hodgkin's ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  6. Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    ... stem cell transplantation from a related or unrelated HLA matched donor. The effect of 5-azacytidine on global gene ...

    Clinical Trial last updated 05/02/2016 - 11:10am.

  7. Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

    ... has been excluded Availability of an 6/6 HLA matched sibling defined by Class I (HLA -A and B) serologic typing (or higher resolution) and Class II (HLA-DRB1) ...

    Clinical Trial last updated 05/09/2016 - 3:58pm.

  8. HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

    ... Donors will be either human leukocyte antigen ( HLA ) compatible unrelated or HLA-genotypically matched related donors (no fully matched sibling donor). ...

    Clinical Trial last updated 05/09/2016 - 3:19pm.

  9. TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate

    ... Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to ...

    Clinical Trial last updated 04/29/2016 - 4:35pm.

  10. Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)

    ... malignancy. Availability of appropriate, willing, HLA -matched related stem cell donor. ...

    Clinical Trial last updated 06/06/2016 - 10:28am.